Sacubitril/Valsartan for Hypertension Without Heart Failure
Sacubitril/valsartan should not be routinely used for hypertension in patients without heart failure, as it lacks cardiovascular outcomes data in this population and is not endorsed by current hypertension guidelines for this indication.
Current Guideline Position
The 2024 ESC Guidelines for hypertension explicitly state that sacubitril/valsartan "awaits supportive evidence from cardiovascular outcomes trials prior to guideline endorsement and routine use in hypertension" 1. While the drug was initially developed for hypertension and demonstrates blood pressure-lowering properties, the guidelines emphasize their requirement for trial evidence showing cardiovascular disease outcomes benefit before recommending any agent for hypertension treatment 1.
FDA-Approved Indication
The FDA approved sacubitril/valsartan exclusively for heart failure with reduced ejection fraction (NYHA functional class II-IV), based entirely on the PARADIGM-HF trial data 2. There is no FDA approval for hypertension as a standalone indication in the United States 2.
Blood Pressure Lowering Evidence
While research demonstrates that sacubitril/valsartan effectively lowers blood pressure:
Meta-analysis data: The 200 mg dose reduced systolic BP by 4.62 mmHg and diastolic BP by 2.13 mmHg compared to ARBs; the 400 mg dose reduced systolic BP by 5.50 mmHg and diastolic BP by 2.51 mmHg versus ARBs 3.
Comparative studies: Sacubitril/valsartan showed superior BP reduction compared to losartan in hypertensive patients 4.
Mechanism: The drug may offer particular benefit for resistant hypertension, central aortic pressure, and nocturnal hypertension through its dual neprilysin inhibition and AT1 receptor blockade 5.
Critical Gap in Evidence
The fundamental problem is the absence of cardiovascular morbidity and mortality outcomes data in hypertensive patients without heart failure 1. The ESC guidelines note that in heart failure trials, BP lowering with sacubitril/valsartan "may have been mediated, in part, by superior BP lowering compared with enalapril," but this does not establish benefit in pure hypertension 1.
Safety Considerations in Hypertension-Only Patients
The safety profile established in heart failure trials may not directly translate:
- Hypotension risk: 18% incidence in PARADIGM-HF, higher than enalapril (12%) 6.
- Angioedema: 0.5% overall incidence, but 2.4% in Black patients 6.
- Hyperkalemia: 12% incidence 6.
- Renal dysfunction: Requires monitoring, particularly in patients with renal artery stenosis 6.
These adverse effects were documented in heart failure patients who underwent run-in periods that excluded 10.5% during enalapril run-in and another 10.4% during sacubitril/valsartan run-in, meaning real-world rates would be higher 6.
When Sacubitril/Valsartan May Be Considered
The only scenario where use might be justified in hypertensive patients:
Concurrent heart failure: Patients with both hypertension and heart failure with reduced ejection fraction (EF ≤40%) should receive sacubitril/valsartan as guideline-directed heart failure therapy, which will simultaneously address their hypertension 2.
Heart failure with preserved EF and hypertension: Post-hoc analysis showed BP lowering in HFpEF patients with resistant hypertension, though this remains investigational 1.
Recommended Approach for Hypertension Without Heart Failure
Use established first-line antihypertensive agents with proven cardiovascular outcomes:
- ACE inhibitors or ARBs (including valsartan alone)
- Calcium channel blockers
- Thiazide or thiazide-like diuretics
- Combination therapy as needed 1
Reserve sacubitril/valsartan for its approved indication until outcome trials in hypertension demonstrate morbidity and mortality benefits 1.
Common Pitfalls to Avoid
Do not prescribe sacubitril/valsartan off-label for hypertension simply because it lowers BP effectively—BP reduction alone does not equal improved cardiovascular outcomes 1.
Do not assume heart failure trial safety data applies to patients without heart failure, as these populations differ substantially 2.
**Do not use in patients with systolic BP <100 mmHg**, severe renal impairment (eGFR ≤30 mL/min/1.73 m²), or potassium >5.2 mmol/L, as these were exclusion criteria in trials 2, 6.